Business Information
The group's principal activity is to discover, develop and markets potential drug candidates for the treatment of diabetes and other metabolic disorders. It has exclusive rights to two drug candidates, which are in late-stage development, for the treatment of diabetes, symlin(TM) (pramlintide acetate) and ac2993 (synthetic exendin-4). Symlin(TM) is a synthetic analog of the human hormone, amylin for the treatment of the people with diabetes who use insulin. Ac2993, a code name for synthetic exendin-4, is for the treatment of type 2 diabetes. The group also has a third drug candidate ac3056, which is in early stage clinical trials. It is used in the treatment of metabolic disorders relating to cardiovascular disease.
|
|
Name |
Title
|
Email
|
| Jeffrey Friedman | Chmn. - Scientific Advisory Board | N/A | | Joseph Cook | Chmn. | N/A | | Robert Sherwin | Chmn. - North American Advisory Board | N/A | | Daniel Bradbury | Dir., CEO, Pres. | N/A | | Lloyd Rowland | VP - Governance, Compliance, Corp. Sec. | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 510,875 | (218,856) | | 2005 | 140,474 | (206,832) | | 2004 | 34,268 | (157,157)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
